Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Conventional Measurements of OLTS with CT Grossly Overestimate the Size of Lesions

When orthopedic surgeons attempt to evaluate and manage osteochondral lesions of the talus (OLTs) using conventional computed tomography (CT), they may overestimate their size. This, in turn, influences treatment strategies. Therefore, OLTs often warrant advanced imaging studies, especially in revision or cases with cystic defects. To determine the effectiveness of these techniques, a study, “Value…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

When orthopedic surgeons attempt to evaluate and manage osteochondral lesions of the talus (OLTs) using conventional computed tomography (CT), they may overestimate their size. This, in turn, influences treatment strategies. Therefore, OLTs often warrant advanced imaging studies, especially in revision or cases with cystic defects. To determine the effectiveness of these techniques, a study, “Value of 3D Reconstructions of CT Scans for Calcaneal Fracture Assessment,” was performed by Foot & Ankle International (FAI).

Understanding the True Anatomy and Size of OLTs May Help Guide Treatment

OLTs are defined as localized irregularities in the articular chondral surface also involving the subchondral bone. The exact cause of these lesions is unclear, but they are likely the result of a rotational ankle injury, such as a ligamentous sprain or bony fracture. OLTs are a common issue in orthopedic medicine; however, treatment remains a clinical challenge.

Most OLTs can initially be managed with nonoperative treatment. When this approach fails, surgery is often indicated. Surgical intervention depends on the chronicity of the lesion, size of the lesion, presence of cystic lesions, and the stability of the cartilage.

Many procedures for larger lesions require autograft or allograft tissue to fill the void, but these procedures can be very costly and do not always address the problem effectively. Understanding the true anatomy and size of these lesions may help better guide treatment, allowing for accurate preoperative planning and potential cost savings.

Conventional CT Scans Overestimate OLT Size

The results of the FAI study showed that conventional measurements of OLTs with CT scans grossly overestimated the size of the lesion. The average approximate OLT volumes from 10 independent observer CT measurements comprised of a rectangular prism (Vrec), a right cylinder (Vcyl), and right cone (Vcone) were compared to morphometric true-volume (MTV) via 3D reconstruction. On average, the Vrec, Vcyl, and Vcone estimates were 303%, 864%, and 285% greater, respectively, than the MTV. The FAI study demonstrates that volume measurements of OLTs using conventional CT typically overestimate true-volume approximations when compared to OLTs created with 3D reconstructions.

CurveBeam Imaging Provides Valuable Insights to Orthopedic Surgeons

3D reconstructions of CT scans are used frequently in orthopedic surgery; however, the usefulness of this technique in OLTs has not been reported in the literature. 3D CT scans, such as those created using CurveBeam Cone Beam CT imaging technology, provide insight previously unavailable through either 2D and plain radiography. These detailed images, like those seen below, provide more precise measurements that can assist surgeons in both accurate diagnosing and preoperative planning.

Bilateral – Talar Head Exposed Sharp Filter: CubeVue, CurveBeam’s custom visualization software, can segment a volume to reveal joint surfaces, such as the talar head.

Talus Navicular Cluster: CurveBeam’s proprietary segmentation tools (under development) are demonstrated here using third-party viewing software.

CurveBeam designs and manufactures Cone Beam CT imaging equipment for the orthopedic and podiatric specialties. CurveBeam’s pedCAT system and CubeVue custom visualization software have been installed in facilities across the United States, Europe, Australia, and China. More recently, CurveBeam’s InReach system, a multi-extremity CT optimized for hand, wrist, and elbow imaging, and LineUP system, a weight-bearing multi-extremity CT for imaging of the foot, ankle, and knee, have been added to the product line. Today, CurveBeam Cone Beam CT scans are setting new standards in orthopedic 3D imaging worldwide.

To find out more, visit https://www.curvebeam.com/about/about-curvebeam/

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512